ArticleFrontiers in immunology2026
Improvement in nasal signs and eosinophils following 3 years of sublingual immunotherapy for allergic rhinitis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of sIgE Qualitative Conversion and Clinical Response to HDMs Sublingual Immunotherapy: Insights from Three Immunoassays.Biomolecules · 2026Article
- From nasal cytology to cellular endotyping: mast cell-eosinophil interactions and overlapping inflammation in allergic rhinitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While sublingual immunotherapy (SLIT) is effective for allergic rhinitis (AR), most studies focus on subjective symptom relief, with limited data on objective signs and biomarkers. This study evaluates the effects of 3-year house dust mite (HDM) SLIT on nasal mucosal signs and peripheral blood eosinophil (EOS) counts in AR patients. Methods: This study retrospectively analyzed the data of 86 AR patients (aged 14-57) who had received 3 years of SLIT treatment. Subjective scores including the total nasal symptom score (TNSS), total medication score (TMS), combined symptom and medication score (CSMS), and visual analog scale (VAS) were assessed at baseline, 1.5 years, and 3 years. Objective assessment of nasal mucosal pathology was performed via nasal endoscopy and quantified using the modified Lund-Kennedy (MLK) scoring system. Additionally, EOS counts and the level of serum total IgE were also measured. Results: At 1.5 and 3 years, significant reductions were observed in TNSS, TMS, CSMS, VAS, and MLK scores compared to baseline and between these timepoints (all Conclusion: Three years of SLIT treatment effectively improved symptoms of HDM-induced allergic rhinitis, significantly reduced signs of nasal mucosal inflammation, and decreased peripheral blood eosinophil counts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.